Impact of fluconazole administration on outcomes in critically ill patients

被引:5
作者
Garrelts, JC
Schroeder, TR
Harrison, PB
机构
[1] Wesley Med Ctr, Clin Pharm Serv & Res, Wichita, KS 67214 USA
[2] Wesley Med Ctr, Infect Dis, Wichita, KS 67214 USA
[3] Wesley Med Ctr, Trauma Program, Wichita, KS 67214 USA
关键词
fluconazole; outcomes; trauma;
D O I
10.1345/aph.1D441
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Serious infections caused by Candida spp. are an increasingly important cause of morbidity and mortality in critically ill patients. it is unclear which patients will benefit from therapy and at what point to institute treatment. OBJECTIVE: To evaluate the impact of administration of fluconazole therapy in critically ill trauma patients on mortality, length of hospital stay, incidence of deep-seated fungal infection, and positive fungal cultures from any site. METHODS: We conducted a retrospective, matched case-control study of 116 critically ill surgical trauma patients who did or did not receive fluconazole. Patients were followed until hospital discharge or death. A consecutive sample of 58 patients who received fluconazole was selected. A parallel group of patients was evaluated, from which 58 were matched with fluconazole-treated patients based on age (+/-5 y), gender, and APACHE II score (+/- 3). RESULTS: The groups of patients were well matched, with the exception of central venous catheter placement and broad-spectrum antibiotic use. We found no difference between groups in hospital mortality (21% vs 26%; p = 0.661) or incidence of deep-seated fungal infection (0% vs 2%; p = NS). However, patients receiving fluconazole had a significantly longer stay in both the intensive care unit (ICU) (18 +/- 13 vs 7 +/- 11 days; p < 0.001) and hospital (25 +/- 15 vs 9 +/- 11 days; p < 0.001). Fluconazole patients were significantly more likely to have Candida cultured from sites associated with colonization (43% vs 2%; p < 0.001), possibly explaining why they received fluconazole. CONCLUSIONS: We were unable to detect a benefit from use of fluconazole in our surgical trauma patient population. Isolation of Candida from the mouth or throat alone, in the absence of correlating clinical signs of infection, should not lead to initiation of fluconazole therapy. Fluconazole use should be reserved for carefully selected patients in the trauma ICU setting.
引用
收藏
页码:1588 / 1592
页数:5
相关论文
共 13 条
  • [1] Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital
    Berrouane, YF
    Herwaldt, LA
    Pfaller, MA
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) : 531 - 537
  • [2] International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections
    Edwards, JE
    Bodey, GP
    Bowden, RA
    Buchner, T
    dePauw, BE
    Filler, SG
    Ghannoum, MA
    Glauser, M
    Herbrecht, R
    Kauffman, CA
    Kohno, S
    Martino, P
    Meunier, F
    Mori, T
    Pfaller, MA
    Rex, JH
    Rogers, TR
    Rubin, RH
    Solomkin, J
    Viscoli, C
    Walsh, TJ
    White, M
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) : 43 - 59
  • [3] Gleason TG, 1997, ARCH SURG-CHICAGO, V132, P1197, DOI 10.1001/archsurg.1997.01430350047008
  • [5] Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients
    Pelz, RK
    Hendrix, CW
    Swoboda, SM
    Diener-West, M
    Merz, WG
    Hammond, J
    Lipsett, PA
    [J]. ANNALS OF SURGERY, 2001, 233 (04) : 542 - 548
  • [6] CANDIDA COLONIZATION AND SUBSEQUENT INFECTIONS IN CRITICALLY ILL SURGICAL PATIENTS
    PITTET, D
    MONOD, M
    SUTER, PM
    FRENK, E
    AUCKENTHALER, R
    [J]. ANNALS OF SURGERY, 1994, 220 (06) : 751 - 758
  • [7] RAFFALLI J, 1998, INT C ANT AG CHEM, V38, P458
  • [8] Practice guidelines for the treatment of candidiasis
    Rex, JH
    Walsh, TJ
    Sobel, JD
    Filler, SG
    Pappas, PG
    Dismukes, WE
    Edwards, JE
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) : 662 - 678
  • [9] ROCCO TR, 2000, ARCH SURG-CHICAGO, V135, P60
  • [10] Safran DB, 1997, ARCH SURG-CHICAGO, V132, P1184, DOI 10.1001/archsurg.1997.01430350034006